PREdiabetes GLycemic Impact and Data Evaluation

Prior treatment

• Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months;

Other illness

• Presence of type 1 or type 2 diabetes;
• Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study;
• Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia;
• Known allergy to sensor materials;
• Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant;

Lab values

• Decompensated liver or kidney diseases (GFR \< 45 ml/min/1. 73 m²);

Other

• Pregnancy or lactation;
• Mental or cognitive impairments that would interfere with study participation;
• Recent use of any CGM within the last 12 months;
• Participation in another clinical study within the last 3 months.

• Age of 18 years and older.
• Presence of prediabetes diagnosed according to criteria of the American Diabetes Association
• Persons who treated with diet and exercise alone or metformin on a stabilized dose for at least 3 months before the study;
• Ability to comply with protocol requirements and maintain a patient diary.
• Signed informed consent.